<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00955240</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000642638</org_study_id>
    <secondary_id>FRE-FNCLCC-ACCORD-16-0708</secondary_id>
    <secondary_id>EU-20941</secondary_id>
    <secondary_id>EUDRACT-2007-0 07029-38</secondary_id>
    <nct_id>NCT00955240</nct_id>
  </id_info>
  <brief_title>Radiation Therapy, Cisplatin, Fluorouracil, and Cetuximab in Treating Patients With Locally Advanced Anal Cancer</brief_title>
  <official_title>Phase II Nonrandomized Multicenter Study of the Impact of Radiochemotherapy (65 Gy + Cisplatin + 5FU) Combined With Cetuximab in Patients Presenting With Locally Advanced Anal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in
      chemotherapy, such as fluorouracil and cisplatin, work in different ways to stop the growth
      of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal
      antibodies, such as cetuximab, can block tumor growth in different ways. Some block the
      ability of tumor cells to grow and spread. Others find tumor cells and help kill them or
      carry tumor-killing substances to them. Giving radiation therapy together with combination
      chemotherapy and cetuximab may kill more tumor cells.

      PURPOSE: This phase II trial is studying giving radiation therapy together with cisplatin,
      fluorouracil, and cetuximab to see how well it works in treating patients with locally
      advanced anal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Evaluate the objective response (complete and partial) 8 weeks after completion of study
           treatment comprising radiotherapy, chemotherapy (fluorouracil and cisplatin), and
           cetuximab followed by additional radiotherapy in patients with locally advanced anal
           cancer.

      Secondary

        -  Evaluate colostomy-free survival.

        -  Evaluate the local control rate (objective response and stabilization) at 8 weeks.

        -  Evaluate relapse-free survival at 5 years.

        -  Evaluate the intermediate objective response at the end of week 5 of radiotherapy.

        -  Evaluate overall survival at 5 years.

        -  Evaluate the duration of response.

        -  Evaluate acute toxicities according to CTCAE v3.0.

        -  Evaluate late toxicities at 5 years according to CTCAE v3.0.

        -  Study the tumor markers associated with response (survival without relapse) and
           toxicity.

        -  Study the genotypes of Fc-receptor immunoglobulins (FCGR2A and FCGR3) and their
           association with skin toxicity, objective survival, and relapse-free survival.

      OUTLINE: This is a multicenter study.

      Patients receive cetuximab IV on days 0, 7, 14, 21, 28, and 35; fluorouracil IV on days 7-10
      and 35-38; and cisplatin IV over 2 hours on days 7 and 35. Beginning on day 7, patients also
      undergo radiotherapy 5 days a week for 5 weeks (weeks 2-6). Two weeks after finishing this
      treatment, patients undergo additional radiotherapy* 5 days a week for 2 weeks (weeks 9 and
      10).

      NOTE: *Some patients may undergo brachytherapy.

      Blood and tissue samples are collected for further analysis.

      After completion of study treatment, patients are followed up for 4 years.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>March 2009</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response (complete and partial) according to RECIST criteria at 8 weeks after completion of study treatment</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival rate at 3 and 5 years</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Colostomy-free survival at 3 and 5 years</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of objective response</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">77</enrollment>
  <condition>Anal Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>cetuximab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed anal cancer

               -  Squamous cell disease

               -  Locally advanced, non-metastatic disease

               -  One of the following clinical TNM stages:

                    -  T2, N0, M0 (largest diameter ≥ 3 cm)

                    -  T3-T4, N0, M0

                    -  Any T, N1-N3, M0

          -  No undifferentiated small cell carcinoma or adenocarcinoma

          -  Measurable disease according to RECIST criteria

          -  Undergone endorectal ultrasound or MRI to evaluate the primary tumor

          -  Undergone thoraco-abdomino-pelvic scan to evaluate tumor extension

          -  Disease suitable to receive radiotherapy and chemotherapy

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-1

          -  Leukocytes ≥ 4,000/mm^3

          -  ANC ≥ 1,500/mm^3

          -  Platelet count ≥ 100,000/mm^3

          -  Hemoglobin ≥ 10 g/dL

          -  Creatinine clearance &gt; 60 mL/min

          -  ALT and AST ≤ 5 times upper limit of normal (ULN)

          -  Alkaline phosphatase ≤ 2.5 times ULN

          -  Total bilirubin ≤ 1.5 times ULN

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  No history of cancer within the past 8 years except for in situ cervical cancer or
             previously treated basal cell carcinoma of the skin

          -  No contraindications to any component of study therapy

          -  No serious uncontrolled illness

          -  No symptomatic grade 1 angina pectoris or angina pectoris ≥ grade 2

          -  No congestive heart failure

          -  No peripheral sensory neuropathy

          -  No uncontrolled diabetes

          -  No HIV positivity

          -  No geographical, social, or psychological situations that preclude medical follow up

          -  Affiliated with a social security system

          -  No patient deprived of liberty or under trusteeship

        PRIOR CONCURRENT THERAPY:

          -  Patients with a diverting colostomy are eligible

          -  No prior excision of this tumor

          -  No prior chemotherapy or radiotherapy for the treatment of this cancer or any other
             history of radiotherapy or pelvic brachytherapy

          -  No concurrent coumarin anticoagulants, phenytoin, sorivudine or brivudine, antacids,
             or allopurinol

          -  Not registered in another clinical trial with an experimental drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Deutsch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gustave Roussy, Cancer Campus, Grand Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Hopital A. Morvan</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Regional Francois Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Departemental</name>
      <address>
        <city>La Roche Sur Yon</city>
        <zip>F-85025</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospital Regional Universitaire de Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Regional Rene Gauducheau</name>
      <address>
        <city>Nantes-Saint Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie Hopital</name>
      <address>
        <city>Paris</city>
        <zip>75248</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint-Louis</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75970</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Prive Saint-Gregoire</name>
      <address>
        <city>Saint-Gregoire</city>
        <zip>35768</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Du Parc</name>
      <address>
        <city>Toulouse</city>
        <zip>31078</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe Oncorad Garonne</name>
      <address>
        <city>Toulouse</city>
        <zip>31300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Alexis Vautrin</name>
      <address>
        <city>Vandoeuvre-les-Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>F-94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 7, 2009</study_first_submitted>
  <study_first_submitted_qc>August 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2009</study_first_posted>
  <last_update_submitted>July 8, 2011</last_update_submitted>
  <last_update_submitted_qc>July 8, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 11, 2011</last_update_posted>
  <keyword>stage II anal cancer</keyword>
  <keyword>stage IIIA anal cancer</keyword>
  <keyword>stage IIIB anal cancer</keyword>
  <keyword>squamous cell carcinoma of the anus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anus Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

